UP421
Phase 1Recruiting 0 watching 0 views this week💤 Quiet
28
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Type1diabetes
Conditions
Type1diabetes
Trial Timeline
Mar 8, 2024 → Jun 1, 2025
NCT ID
NCT06239636About UP421
UP421 is a phase 1 stage product being developed by Sana Biotechnology for Type1diabetes. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06239636. Target conditions include Type1diabetes.
Hype Score Breakdown
Clinical
10
Activity
5
Company
5
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06239636 | Phase 1 | Recruiting |
Competing Products
2 competing products in Type1diabetes
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Dapagliflozin + Placebo Oral Tablet | AstraZeneca | Phase 1 | 33 |
| XeriSol glucagon | Xeris Pharmaceuticals | Phase 1 | 28 |